During the September quarter, the clinical-stage immuno-oncology company continued to progress clinical programs and remains well-funded to cater...
Pharma & Biotech
OTC Markets
Small caps
Pharma & Biotech
Small caps
OTC Markets
Small caps
OTC Markets
OTC Markets
OTC Markets
Small caps
Lexaria Bioscience seeing increased demand for its DehydraTECH drug delivery system
DehydraTECH masks unwanted taste, improves onset speed and increases bioavailability of active...
The company is well-funded to deliver on commercial and clinical milestones including the...
A study has also shown that lead drug Ampligen can decrease the infectious viral yield of...
The company plans a Phase 2 study of FSD201 in more than 300 COVID-19 patients in October this year
The company’s lead drug otenaproxesul, formerly known as ATB-346, could be a home run if it...
Canntab Therapeutics (CSE: PILL-OTCQB: CTABF) CFO Richard Goldstein joined Steve Darling from Proactive Vancouver with news the company has announced the launch of its suite of hard pill cannabinoid formulations in Australia with its partner CANN Global Ltd. Goldstein takes Proactive through...
Pharma & Biotech
CytoDyn provide update on their path to approval for treatment of...
Medical technology & services
Market Report: FTSE gets an injection of optimism from US...
Pharma & Biotech
Cardiol Therapeutic’s Cortalex THC free CBD product now available...
Mining
Retail & consumer
Get our market previews and stories before the main networks.
Not just the FTSE. Read about
opportunities from the whole
equities market.
Hear directors at first-hand
or meet them in person at our events.
Watch IPOs and access on the same terms as the institutions.
